Reed Miller
Manager, Commercial/R&D

Reed focuses on new technology development, including clinical trials and investment start-up companies. He has been covering medical technology since joining Medtech Insight predecessor Gray Sheet in 2000, and also covered cardiovascular technology for theheart.org and drug industry compliance issues for HCPro. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.
Latest From Reed Miller
Exec Chat: Abbott’s Burton Talks About Abbott’s Plans To Address Chronic Pain With SCS
Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s new labeling for Abbott’s spinal cord stimulation devices that includes non-surgical back pain.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
Pear Bankruptcy Filing Highlights Difficult Challenges Facing Digital Therapeutics
Pear Therapeutics filed for Chapter 11 bankruptcy in April and sold its remaining assets in an auction for about $6m. The demise of one the pioneers in the prescription digital therapeutics industry highlights the challenges PDT developers face getting their products reimbursed.
News We’re Watching: Premom Data Privacy Settlement, Labcorp Owes $372m For Patent Violations, Elixir Stent Trial Success
This week, the DC Attorney General announced a settlement with ovulation-tracking app Premom; a novel scoliosis treatment won FDA approval; research showed Fractyl Health’s Rejuva delivery system can deliver gene therapy directly to the pancreas; and BearCare recalled a thermometer over burn risks.
Minute Insight: FDA Approves Abbott’s SCS For Non-Surgical Back Pain
The approval, supported by the results of the randomized DISTINCT trial, includes all of Abbott’s spinal cord stimulation devices that deliver the proprietary BurstDR waveform.